Acceptability of depo-subq in uniject: Results from Uganda and Senegal
Learning Areas:Planning of health education strategies, interventions, and programs
Identify five strategies to consider when introducing depo-subQ in Uniject into an existing family planning program Discuss three factors to consider when introducing depo-subQ in Uniject into a community-based distribution program
Keyword(s): International Family Planning, Community-Based Health Care
Organization/institution whose products or services will be discussed: Depot medroxyprogesterone acetate for subcutaneous injection (104 mg/0.65 mL suspension for injection) in the Uniject™ injection system is manufactured by Pfizer, Inc. as SAYANA PRESS®, approved by the UK MHRA, but not yet registered in Uganda or Senegal
Qualified on the content I am responsible for because: I am the principal investigator of the study being presented. Previously, I evaluated a communication campaign in Kenya aimed at increasing contraceptive continuation rates among DMPA users. I also led a study to determine the factors which motivate young women to use implants and what influences their decisions to continue or switch methods. I have over a decade of experience conducting qualitative and quantitative research to expand understanding of complex contraceptive and HIV prevention behaviors.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.